For those that kept saying trial design etc wasn't possible I followed up on what others have done. With SPL if they were to proceed with trials to get into othe rmarkets it will be interesting to see what design they would choose? The cost of these trials would be interesting.
The Thai university one during lockdown is very interesting and a study that unless going to a country that has lockdowns again will be hard to repeat but these guys took the opportunity and got a study complete and got the data
Nice innovation in getting a trial done with a reasoable scale.
https://sanotize.com/clinical-trials-covid/Phase III trial for COVID-19 prevention
(ongoing)SaNOtize is enrolling participants in a Phase III efficacy study to evaluate NONS™ as an antiviral preventing COVID-19 infection. This double-blinded, placebo controlled clinical trial is Health Canada-approved and is recruiting up to 4,000 volunteers in Canada and Sri Lanka.
Clinical trial registry: Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection
For Canadian site enrollment information, please see here.
Retrospective clinical study for COVID-19 prevention after exposure
(completed April 2022)Participants in the recent study included 625 students at a university in Thailand that was undergoing quarantine for an Omicron outbreak. Those with confirmed exposure to COVID-19 were offered the option to take nitric oxide nasal spray (NONS™) as a possible preventive measure against infection. Nitric oxide is a naturally occurring molecule known to have antimicrobial properties, including a direct effect on SARS-CoV-2, the virus that causes COVID-19. Those who chose to use NONS™ (203 participants) sprayed it intranasally at least four times daily (422 volunteers chose not to use NONS). The infection rate in participants who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001), representing a significant reduction in infection risk of 75%. Adverse events were all mild (nasal discomfort, 3.9% of NONS participants).
Phase III clinical trial for COVID-19 treatment
(completed Jan 2022)This study was a randomized, double-blind, placebo-controlled study that took place at 20 clinical sites across India and enrolled 306 patients who had contracted COVID-19. In the NONS™ treatment group,the SARS-CoV-2 viral load was reduced by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours, compared to participants using a saline nasal spray (placebo). The median time to a negative PCR test in this group was 4 days in the treatment group compared with 8 days in the control. More patients taking NONS™ were also asymptomatic by the end of the 16-day study compared to those taking placebo. Mild adverse events were observed in NONS participants (6.5%, nasal discomfort) compared to 2.7% in the placebo group.
Although the study was designed only to assess treatment, it also looked at infection rates of people in close contact with study participants: the NONS household infection rates remained stable, while infections in placebo households increased, hinting at a potential role in prevention (no statistics were run on the close contacts data).
Data was published in THE LANCET Regional Health Southeast Asia:
- Forums
- ASX - By Stock
- Time for action!
For those that kept saying trial design etc wasn't possible I...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.64M |
Open | High | Low | Value | Volume |
9.7¢ | 9.7¢ | 9.5¢ | $19.64K | 204.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 69731 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 5390 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 69731 | 0.095 |
2 | 305855 | 0.094 |
2 | 320000 | 0.093 |
1 | 100000 | 0.092 |
4 | 49861 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 5390 | 1 |
0.098 | 200000 | 1 |
0.100 | 106000 | 3 |
0.105 | 148467 | 3 |
0.110 | 183058 | 5 |
Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |